Lord, Abbett & Co
CORT icon

Lord, Abbett & Co’s Corcept Therapeutics CORT Stock Holding History

Lord, Abbett & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-203,332
Closed -$3.92M – 867
2017
Q3 		$3.92M Sell
203,332
-362,058
-64% -$5.4M 0.01% 800
2017
Q2 		$6.67M Sell
565,390
-259,362
-31% -$2.82M 0.02% 721
2017
Q1 		$9.04M Sell
824,752
-9,167
-1% -$80.5K 0.03% 631
2016
Q4 		$6.05M Buy
833,919
+630,429
+310% +$4.94M 0.02% 703
2016
Q3 		$1.32M Buy
+203,490
New +$1.18M ﹤0.01% 845

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Lord, Abbett & Co's CORT Position: Q4 2017 in Review

Lord, Abbett & Co sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 203,332 shares — an estimated $3.92M sold.

Lord, Abbett & Co first reported a position in CORT in Q3 2016 and held it in 5 quarters. The position peaked at $9.04M in Q1 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • Lord, Abbett & Co reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 203,332 Corcept Therapeutics shares in Q4 2017, an estimated $3.92M.
  • Lord, Abbett & Co first reported a position in Corcept Therapeutics in Q3 2016 and held it in 5 quarters.
  • Lord, Abbett & Co's Corcept Therapeutics position peaked at $9.04M in Q1 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Lord, Abbett & Co's 13F filing for Q4 2017, filed 14 Feb 2018.